Welcome to the
NUVISAN DIGITAL CONGRESS

New Targets l New Molecules l New Companies

This virtual conference aims at connecting topics and scientists across the pharma, biotech, venture capital, and CRO industries to discuss the recent promises and challenges of the new pharma ecosystem.

→ Read more about the Congress

REGISTER FOR FREE & JOIN THE SCIENTIFIC CIRCLE

Be part of the new scientific circle and discuss the promises and challenges of the new pharma ecosystem with our 14 speakers.

→ Register here for free

Speakers & Hosts

Speakers

Dr. Zachary Sweeney

CEO

Interline Therapeutics

Dr. Alexander Hillisch

Vice President, Head of Computational Molecular Design

Bayer AG

Dr. Anna Hirsch

Head of the drug design and optimization department

Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)

Dr. Christian Hackenberger

DEPARTMENT HEAD / PROFESSOR

Leibniz-Institut für Molekulare Pharmakologie (FMP) and the Humboldt Universität zu Berlin (HU Berlin)

Dr. Dirk Trauner

Janice Cutler Chair in Chemistry and Adjunct Professor of Neuroscience and Physiology

New York University

Dr. Norbert Schmees

Director, Head of Life Science Chemistry

NUVISAN ICB GmbH

Dr. Ralf Altmeyer

CEO

Medusa Therapeutics

Dmitrij Hristodorov

Partner

FORBION

Dr. Christian Heinis

Associate Professor

Swiss Federal Institute of Technology in Lausanne

Dr. Andreas Bender

Director, Head of Digital Life Sciences

NUVISAN ICB GmbH

Hosts

Franz von Nussbaum

EVP and Head of Life
Science Chemistry

NUVISAN ICB GmbH

Jörg Fanghänel

EVP and Head of
Lead Discovery

NUVISAN ICB GmbH

Uyen Nguyen

Head of Laboratory
Screening

NUVISAN ICB GmbH

About NUVISAN

The NUVISAN group is a Contract Research Organization (CRO) and Contract Manufacturing Organization (CDMO) with its headquarters in Neu-Ulm and six sites in Germany and France (Neu-Ulm, Berlin, Grafing, Gauting, Waltrop and Sophia-Antipolis) in addition to monitoring activities with offices in Argentina, Peru and Brazil as well as in the USA.

NUVISAN offers integrated and coupled services and solutions along the drug development value chain from target identification to the patient with all supporting services (DMPK, GMP synthesis, formulation development and analysis, bioanalysis, Phase 1 CPU, clinical trial supplies and monitoring).

→ Read more about NUVISAN

Contact Digital Congress Organisation

NUVISAN Pharma Holding GmbH
Elmar Rothenfusser | +49 731 9840 143 | elmar.rothenfusser@nuvisan.com
Valeria Vasiliev | +49 731 9840 481 | valeria.vasiliev@nuvisan.com
Wegenerstr. 13 | 89231 Neu-Ulm | Germany